Suzhou Ribo Life Science Co., Ltd. launches new milestone in anti-thrombotic pipeline: Another new siRNA drug submitted for Phase II clinical application, continuing to release the therapeutic potential of small nucleic acids - Suzhou Suzhou Ribo Life Science Co., Ltd. Technology Co., Ltd.
May 28, 2026·Suzhou, China Mölndal, Sweden
Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals (collectively known as "Suzhou Ribo Life Science Co., Ltd.") announced that they have submitted a Phase II clinical trial application (CTA) to the European Medicines Agency (EMA) for the small nucleic acid drug RBD1119 for the treatment of coronary artery disease. Recently, based on the RiboGalSTAR TM liver-targeted siRNA platform, Suzhou Ribo Life Science Co., Ltd. has simultaneously promoted the clinical development of multiple siRNA drugs in subdivided areas including atrial fibrillation and venous thromboembolism, creating the world's leading anticoagulant/antithrombotic small nucleic acid landscape, aiming to systematically solve the root treatment gap of thromboembolic diseases. This CTA submission for coronary artery disease marks another important development of Suzhou Ribo Life Science Co., Ltd.'s major layout in the field of anti-thrombosis, and its confidence in continuing to expand the broad application of small nucleic acids in this field.
Coronary artery disease (CAD) is the leading cause of morbidity and death in patients with cardiovascular disease worldwide. Its core cause is the formation of atherosclerotic plaques and the resulting thrombotic complications such as myocardial infarction and ischemic events. At present, antiplatelet and anticoagulant treatments are routine clinical methods, but the risk of thrombotic events in patients with stable coronary artery disease (CAD) after standard optimized treatment is still not fully controlled. The major limitation of existing therapies is the high risk of bleeding, which limits the intensity of treatment and long-term medication regimens for many patients. Therefore, in response to the current dilemma of antithrombotic treatment, there is an urgent need to develop new therapies that can achieve efficient and long-term prevention and treatment of thromboembolism while controlling the risk of bleeding, and achieve a therapeutic effect that balances efficacy and safety.
Dr. Anders Gabrielsen, Chief Medical Officer of Suzhou Ribo Life Science Co., Ltd., said: "Cardiovascular disease is one of Suzhou Ribo Life Science Co., Ltd.'s key therapeutic areas. We are very pleased to advance another anti-thrombotic siRNA drug to the next stage of clinical development, which once again proves our firm commitment to using leading small nucleic acid therapies to provide clinical solutions with a better benefit/risk ratio for patients who currently lack adequate treatment."